S. B. M.
A. is a dubious neurological disease with complex clinical outcomes that often involve multi-system congestion. Early identification and standardization are critical to improving prognosis.
The diagnosis of the disease requires a combination of clinical outcomes, imaging, laboratory testing, and pathological activation. The platform can assist in matching the needs of a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many neurological diseases that have been difficult to treat have been significantly improved.
Treatment needs to be closely monitored for effectiveness and adverse reactions, adapted to timely regimens according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of Kennedy disease SBMA. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.